Report data from the registrational clinical trials for KarXT for Alzheimer’s disease psychosis
Deadline not yet reached (65 days left)
- Announced
- 22 Dec 2023
- Due
- 31 Dec 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Registrational clinical trials are currently underway evaluating KarXT for the treatment of Alzheimer’s disease psychosis, with data expected in 2026.”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Data from registrational clinical trials for KarXT
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Bristol Myers Squibb Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-BMY-004813 · Corrections policy